Related content

Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma

By Su Ying-Wen   Chang Ming-Chih   Chiang Ming-Fu   Hsieh Ruey-Kuen  

Journal of Neuro-Oncology, Vol. 71, Iss. 3, 2005-02 ,pp. : 315-318

Springer Publishing Company

Access to resources Recommend Favorite

Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

By Zuniga Richard   Torcuator Roy   Jain Rajan   Anderson John   Doyle Thomas   Schultz Lonni   Mikkelsen Tom  

Journal of Neuro-Oncology, Vol. 99, Iss. 2, 2010-09 ,pp. : 237-242

Springer Publishing Company

Access to resources Recommend Favorite

Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials

By Hofer Silvia   Elandt Katarzyna   Greil Richard   Hottinger Andreas F.   Huber Urs   Lemke Dieter   Marosi Christine   Ochsenbein Adrian   Pichler Josef   Roelcke Ulrich   Weder Patrik   Zander Thilo   Wick Wolfgang   Weller Michael  

Acta Oncologica, Vol. 50, Iss. 5, 2011-06 ,pp. : 630-635

Informa Healthcare

Access to resources Recommend Favorite

Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation

By Combs S.   Ahmadi R.   Schulz-Ertner D.   Thilmann C.   Debus J.  

Journal of Neuro-Oncology, Vol. 71, Iss. 3, 2005-02 ,pp. : 319-323

Springer Publishing Company

Access to resources Recommend Favorite

Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival

By Chen Christina   Huang Raymond   MacLean Ainsley   Muzikansky Alona   Mukundan Srinivasan   Wen Patrick   Norden Andrew  

Journal of Neuro-Oncology, Vol. 115, Iss. 2, 2013-11 ,pp. : 267-276

Springer Publishing Company

Access to resources Recommend Favorite